GVR Report cover Real-time PCR, Digital PCR, And End-point PCR Market Size, Share & Trends Report

Real-time PCR, Digital PCR, And End-point PCR Market Size, Share & Trends Analysis Report By Technology (Quantitative, Digital, End-point), By Product, By Application, And Segment Forecasts, 2022 - 2030

  • Report ID: GVR-1-68038-552-6
  • Number of Pages: 120
  • Format: Electronic (PDF)
  • Historical Range: 2017 - 2020
  • Industry: Healthcare

Report Overview

The global real-time PCR, digital PCR, and end-point PCR market size was valued at USD 31.64 billion in 2021 and is expected to decline at a compound annual growth rate (CAGR) of 8.2% from 2022 to 2030. The decrease in the demand for PCR testing for COVID-19 testing is expected to decline the market growth. However, the global real-time PCR(qPCR), digital PCR(dPCR), and end-point PCR market without the impact of the COVID-19 pandemic is expected to expand at a compound annual growth rate (CAGR) of 8.0% from 2022 to 2030. Polymerase chain reaction (PCR) uses polymerase enzyme, primers, and repeated thermal cycles to make limitless DNA copies from a single strand. Because these tests are performed in automated thermal cyclers, they are less sensitive to cross-contamination. Technological advancement is increasing the demand for molecular testing. dPCR and qPCR are commonly used diagnostic procedures used in research, pharmaceutical, and biotech organizations, and have a wide range of applications.

U.S. real-time PCR, digital PCR, and end-point PCR market size, by application, 2020 - 2030 (USD Billion)

The COVID-19 pandemic has had a significant impact on the healthcare industry. The diagnostic industry was the hardest hit, with exponential growth in the market. As they are used for diagnostic and drug development, digital PCR and real-time PCR have seen a lot of interest. Therefore, the industry vendors are increasingly focusing on building droplet digital PCR kits to detect COVID-19. Moreover, many market players have introduced innovative instruments and novel tests for COVID-19 testing. For instance, in September 2020, the U.S. FDA approved Emergency Use Authorization (EUA) for Bio-Rad’s SARS-CoV-2 ddPCR Kit for the detection of SARS-CoV-2 infection.  In addition, regulatory agencies have expressed strong support for approving these tests to mitigate the impact of the COVID-19 outbreak. Thus, it will boost market growth.

Several companies' marketing strategies have been altered to cope with the pandemic and increase revenue. In addition, major market players are concentrating on new technologies to expand the industry. For instance, to address the COVID-19 outbreak, in March 2020, Thermo Fisher developed several PCR kits and assays for diagnostic and research purposes. SARS-CoV-2 multiplex real-time PCR test gained emergency use authorization (EUA) from the US FDA, and AcroMetrix Coronavirus 2019 (COVID-19) RNA Control was introduced in 2020. Such market players’ initiatives are expected to open new opportunities in the market.

The increasing incidence of genetic disorders and major infectious diseases, growing utilization of biomarker profiling for disease diagnostics, and the successful execution of the Human Genome Project are the primary factors increasing the demand for technologically advanced PCR tests over the forecast period. In the coming years, significant technological breakthroughs in technologies, increasing investments, funding, and grants are likely to increase the demand for digital PCR in different applications. 

Consumer preferences for early disease detection and treatment have accelerated research and development into novel genetic techniques and product creation. Furthermore, increased investment and the accessibility of cash and grants are supporting this surge in R&D activity. Moreover, governments and federal organizations all over the world are increasingly emphasizing the importance of qPCR and dPCR technologies in genomics research. In addition, several financing efforts by government and corporate organizations to assist genomic research have been seen in the qPCR and dPCR industries during the last decade. 

Application Insights

The clinical segment held the largest revenue share of over 85.0% in 2021. This can be attributed to various factors, such as the rising prevalence of diseases including cancer, infectious diseases, and diabetes; high precision of testing methods; increasing commercialization of reagents for diagnostics; efficient disease diagnosis, monitoring, and treatment; and additional benefits in disease detection. For instance, in April 2019, The QuantStudio 6 & 7 Pro RT-PCR Systems, which incorporate additional features such as facial identification, voice assistant, and RF identification, were introduced by Thermo Fisher Scientific Inc. Similarly, in January 2019, QIAGEN has announced the development of a new generation of digital polymerase chain reaction equipment. Compared to currently available digital PCR technologies, it provides highly automated workflows with substantially faster time-to-result, more multiplexing, and greater throughput flexibility.

The forensic segment is expected to register the fastest growth rate over the forecast period. The increasing use of novel techniques in forensic applications such as DNA typing, genetic fingerprinting, and DNA testing is anticipated to drive the segment over the forecast period. Moreover, improvements in existing technologies to prepare the library for forensic DNA typing from difficult samples are driving the segment.

Product Insights

The consumables and reagents segment held the largest revenue share of over 60.0% in 2021. This can be attributed to the outbreak of the COVID-19 pandemic, increased demand for earlier detection of disease, and the number of significant companies manufacturing digital PCR consumables and reagents. Furthermore, the widespread use of consumables and reagents and expanding demand for healthcare, research, and other purposes are supporting the large segment share. Moreover, the segment is anticipated to maintain its lead throughout the forecast period.

Moreover, the rising incidence of chronic conditions and the growing use of PCR has increased the requirement for consumables and reagents. Furthermore, the pharmaceutical and healthcare industries' rising acceptance of technology innovations and increased research and development will generate the significant potential for this market throughout the anticipated period. 

Technology Insights

The quantitative PCR segment held the largest revenue share of over 85.0% in 2021. This segment is driven by factors such as rapid technological advancements and increasing demand for automated systems and point-of-care diagnostics. In addition, the high adoption of technology supported by the introduction of products based on real-time PCR for screening and diagnosis of COVID-19 has increased the segment growth at an exponential rate. For instance, in March 2020, Bruker Corporation announced a distribution agreement with the subsidiary of Novacyt SA for the distribution of genesig real-time PCR coronavirus assay in the U.S., the U.K., Spain, France, and Germany.

U.K. real-time PCR, digital PCR, and end-point PCR market share, by technology, 2021 (%) 

Digital PCR is a next-generation diagnostic technology for precise nucleic acid measurement. These systems have higher sensitivity and accuracy than other PCR-based techniques, which is expected to drive the market forward throughout the forecast period. Moreover, the increasing introduction of innovative Droplet Digital PCR tests is anticipated to increase the application expansion over the forecast period.

Regional Insights

North America dominated the global market with a revenue share of over 35.0% in 2021and is expected to maintain its position during the forecast period, majorly due to the presence of favorable regulations and various initiatives about the development of healthcare infrastructure undertaken by the government and high disease prevalence in the region. Furthermore, the strong presence of prominent manufacturers and an expanding requirement for rapid diagnostic tests in the region are expected to serve as critical factors driving the North American market throughout the forecast period.

Asia Pacific is the most lucrative market due to the presence of significant developments by China and Japan for technological integration of PCR methodologies, and the development of healthcare, R&D, and clinical development frameworks of emerging economies such as India and Australia has poised the Asia Pacific. The market to witness lucrative growth opportunities throughout the forecast period.

Key Companies & Market Share Insights

Major market players are adopting marketing strategies such as geographical expansion, partnerships, strategic collaborations, and mergers and acquisitions in emerging and economically favorable regions. For instance, in February 2022, F. Hoffmann-La Roche Ltd expanded the COVID-19 PCR tests in countries accepting the CE market. Company expansion is anticipated to increase its share in the market. Some prominent players in the global real-time PCR, digital PCR, and end-point PCR market include:

  • Abbott

  • Qiagen

  • Bio-Rad Laboratories Inc.

  • Agilent Technologies, Inc.

  • Thermo Fisher Scientific, Inc.

  • GE Healthcare


  • F. Hoffmann-La Roche Ltd.

  • Fluidigm Corporation 

Real-time PCR, Digital PCR, And End-point PCR Market Report Scope 

Report Attribute


Market size value in 2022

USD 32.76 billion

Revenue forecast in 2030

USD 14.63 billion

Growth rate

CAGR of 8.2% from 2022 to 2030

Base year for estimation


Historical data

2017 - 2020

Forecast period

2022 - 2030

Quantitative units

Revenue in USD million/billion and CAGR from 2022 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Technology, application, product, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; Germany; U.K.; France; Italy; Spain; China; Japan; India; Australia; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE

Key companies profiled

Bio-Rad Laboratories; Thermo Fisher Scientific Inc.; Qiagen; Abbott; Agilent Technologies, Inc.; bioMerieux; Fluidigm Corporation; F. Hoffmann-La Roche Ltd.

Customization scope

Free report customization (equivalent to up to 8 analyst working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail of customized purchase options to meet your exact research needs. Explore purchase options


Segments Covered in the Report

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2017 to 2030. For this report, Grand View Research has segmented the global real-time PCR, digital PCR, and end-point PCR market report based on technology, product, application, and region:

  • Technology Outlook (Revenue, USD Million, 2017 - 2030)

    • Quantitative

      • Consumables & Reagents

      • Instruments

      • Software & Services

    • Digital

      • Consumables & Reagents

      • Instruments

      • Software & Services

    • End-point

      • Consumables & Reagents

      • Instruments

      • Software & Services

  • Product Outlook (Revenue, USD Million, 2017 - 2030)

    • Consumables & Reagents

    • Instruments

    • Software & Services

  • Application Outlook (Revenue, USD Million, 2017 - 2030)

    • Clinical

      • Pathogen Testing

      • Oncology testing

      • Blood Screening

      • Liquid Biopsy

      • dPCR-based Non-invasive Prenatal Testing (NIPT)

      • Others

    • Research

      • Stem Cell Research

      • DNA Cloning & Sequencing

      • Recombinant DNA Technology

      • Rare Mutation Detection

      • Gene Expression

      • Single Cell Analysis

      • Microbiome Analysis

      • Copy Number Variation Analysis

      • Library Quantification (NGS)

      • Characterization of Low-fold Changes in mRNA and miRNA

      • Expression"

      • Species Identification

      • GMO Detection

      • Others

    • Forensic

  • Regional Outlook (Revenue, USD Million, 2017 - 2030)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

      • France

      • Italy

      • Spain

    • Asia Pacific

      • Japan

      • China

      • India

      • Australia

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

      • UAE

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon